The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

Police traffic officers do not need a reason to stop a vehicle, but they must have a “reasonable suspicion” that the motorist ...

The UK injectable drug delivery market is set to grow at 8.80% CAGR through 2034, driven by rising obesity rates and the approval of weight-loss injectable.